Asunto(s)
Fosfatasa Alcalina/análisis , Enfermedades Óseas Metabólicas/enzimología , Huesos/enzimología , Adolescente , Factores de Edad , Densidad Ósea , Huesos/metabolismo , Niño , Preescolar , Femenino , Humanos , Técnicas para Inmunoenzimas , Lactante , Recién Nacido , Masculino , Valores de Referencia , Factores SexualesRESUMEN
The usefulness of bone turnover markers in Gaucher disease is still unclear and their utility in monitoring the effects of enzyme replacement therapy (ERT) on bone metabolism has not yet been investigated exhaustively. Skeletal involvement seems to improve slowly during ERT, but only a few studies evaluating bone mineral density (BMD) changes during a long follow-up period have been reported. The aim of this study was to assess the efficacy of ERT on bone involvement in a group of 12 type I Gaucher disease (GD I) patients by monitoring biochemical indices of bone resorption/formation and BMD measured by dual energy x-ray absorptiometry (DEXA). Serum (calcium, phosphorus, bone alkaline phosphatase isoenzyme, carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal telopeptide of type I collagen (ICTP), osteocalcin, intact parathyroid hormone) and urinary (calcium, phosphorus, hydroxyproline and free deoxypyridinoline) markers of bone metabolism and lumbar BMD were measured at baseline, after 6 and 12 months, and then every year for a mean ERT follow-up period of 4.5 years (range 4.4-6 years). Twelve healthy adult subjects matched for age and sex were tested as negative controls. A significant decrease of PICP was detected in the patient group at baseline (mean value 100.52 ng/ml vs 142.45 ng/ml, p = 0.017), while ICTP was remarkably higher: mean value 3.93 ng/ml vs 2.72 ng/ml, p = 0.004 (two-sided Student's t-test). No changes in bone formation indices were observed during the follow-up period, while urinary calcium excretion increased significantly from 0.065 to 0.191 mg/mg creatinine (p = 0.0014) (repeated measures ANOVA). A significant BMD improvement was also detected after an average ERT period of 4.5 years: Z-score increased from -0.81 to -0.56 (p = 0.005) (two-sided Student's t-test). These data evidenced the ineffectiveness of the biochemical markers used in monitoring ERT efficacy in GD I skeletal involvement, whereas DEXA was demonstrated to be a reliable method with which to follow up BMD improvement.
Asunto(s)
Densidad Ósea/efectos de los fármacos , Terapia Enzimática , Enfermedad de Gaucher/patología , Absorciometría de Fotón , Biomarcadores/química , Huesos/efectos de los fármacos , Huesos/metabolismo , Estudios de Casos y Controles , Femenino , Estudios de Seguimiento , Enfermedad de Gaucher/terapia , Humanos , Vértebras Lumbares/patología , Masculino , Factores de TiempoRESUMEN
Bone involvement is one of the most disabling aspects of type I Gaucher disease and its pathophysiology is still not well understood. As an invasive procedure, bone biopsies are not appropriate in a large population study. The development of sensitive bone resorption and formation tests have allowed the authors to study bone metabolism in a noninvasive manner in a group of type 1 Gaucher patients. Ten type I Gaucher adult patients with mild-to-severe bone disease were evaluated. Bone mineral density and markers of bone formation (total alkaline phosphatase and isoenzymes, carboxyterminal propeptide of type I procollagen, osteocalcin) and resorption (carboxyterminal telopeptide of type I collagen, urinary hydroxyproline, free-deoxypyridinoline and calcium) were measured in patients and in a control group, matched for sex and age. In Gaucher patients, carboxyterminal propeptide of type I procollagen (PICP), a bone formation index, was significantly lower compared with normal subjects (mean 101.17 ng/ml vs 140.75 ng/ml, P = 0.038), and analysis of bone resorption indexes showed a significant increase (mean 4.24 ng/ml vs 2.87 ng/ml, P = 0.012) of serum carboxyterminal telopeptide of type I collagen (ICTP). No significant differences were observed in osteocalcin, alkaline phosphatase, and urinary hydroxyproline. Bone mineral density revealed osteopenia in six patients, with a mean Z-score of ?1.04. It was not possible to show a relationship between sex, splenectomy status, age, weight, spleen, and liver volume and bone density, expressed as a Z-score nor a correlation between Z score and severity of skeletal disease. Results have shown a predominance of the resorption phase in the bone metabolism of Gaucher patients. These markers could be useful in monitoring the effect of enzyme replacement therapy on Gaucher disease skeletal involvement.
Asunto(s)
Remodelación Ósea , Enfermedad de Gaucher/metabolismo , Vértebras Lumbares/metabolismo , Absorciometría de Fotón , Adulto , Fosfatasa Alcalina/metabolismo , Aminoácidos/orina , Biomarcadores/análisis , Densidad Ósea , Colágeno/sangre , Colágeno Tipo I , Femenino , Enfermedad de Gaucher/patología , Humanos , Hidroxiprolina/orina , Isoenzimas , Masculino , Fragmentos de Péptidos/sangre , Péptidos/sangre , Procolágeno/sangreRESUMEN
This prospective, randomized, controlled study compared the effects of recombinant human FSH (r-hFSH) and highly purified urinary FSH (u-hFSH HP) on lipoprotein(a) [Lp(a)] concentrations in women undergoing ovarian stimulation. Fifty infertile women were randomly allocated into two equally sized treatment groups (n = 25 per group). Thirty normal ovulation women were recruited as controls. The infertile women received u-hFSH or r-hFSH 150 IU/day starting on cycle day 2. From cycle day 6 the dose was adjusted according to ovarian response. Human chorionic gonadotrophin 10,000 IU was administered once there was at least one follicle > or =18 mm in diameter. The luteal phase was supported with progesterone 50 mg/day for at least 15 days. Repeated measurements of Lp(a) concentrations were performed during both stimulated and natural cycles. A significant increase in luteal phase Lp(a) concentrations was detected in the stimulated cycles, whereas no significant changes in serum Lp(a) concentrations were observed during natural cycles. There were no significant differences between the urinary and recombinant FSH effects on serum Lp(a). The luteal Lp(a) increase was transitory because after 1 month Lp(a) concentrations returned to baseline values if pregnancy failed to occur; in pregnant women persistent increased Lp(a) concentrations were found at the 8th week. The percentage changes in serum Lp(a) were positively correlated with the luteal progesterone increase (r = 0.40, P < 0.05), but not with follicular or luteal oestradiol increase. The women with low baseline Lp(a) (< or =5 mg/dl) had a greater increase of the Lp(a) concentrations at midluteal phase than women with baseline Lp(a) >5 mg/dl. In conclusion, the recombinant or urinary hFSH administration does not directly influence Lp(a) concentrations. The luteal Lp(a) increase in stimulated cycles is not related to gonadotrophin treatment per se, but appears to be related to the high luteal progesterone concentrations, physiologically or pharmacologically determined. Our results also suggest that the sensitivity to the progesterone changes could be related to apolipoprotein(a) phenotype.
Asunto(s)
Hormona Folículo Estimulante/uso terapéutico , Lipoproteína(a)/sangre , Ciclo Menstrual/sangre , Ovario/efectos de los fármacos , Orina/química , Adulto , Estudios de Casos y Controles , Gonadotropina Coriónica/farmacología , Femenino , Hormona Folículo Estimulante/aislamiento & purificación , Humanos , Infertilidad Femenina/sangre , Infertilidad Femenina/tratamiento farmacológico , Infertilidad Femenina/fisiopatología , Fase Luteínica/metabolismo , Ciclo Menstrual/efectos de los fármacos , Embarazo , Progesterona/metabolismo , Progesterona/uso terapéutico , Estudios Prospectivos , Proteínas Recombinantes/uso terapéutico , Valores de Referencia , Factores de TiempoAsunto(s)
Fosfatasa Alcalina/metabolismo , Enfermedad de Gaucher/enzimología , Isoenzimas/metabolismo , Adulto , Fosfatasa Alcalina/química , Femenino , Enfermedad de Gaucher/tratamiento farmacológico , Glucosilceramidasa/uso terapéutico , Humanos , Isoenzimas/química , Hígado/enzimología , Masculino , Persona de Mediana Edad , Valores de ReferenciaRESUMEN
BACKGROUND: The clotting state of the blood changes according to the type of physical exercise to which a group of healthy subjects are subjected. We studied the behaviour of the coagulation system before and after near-maximum, specific and standardized exercise tests in three groups of males practising sports defined as demanding in terms of cardiovascular output. METHODS: The study was a comparative investigation between athletes and the group of controls composed of presumably healthy males. SETTING: athletes training for competitions such as marathon, rowing and weightlifting. PARTICIPANTS AND INTERVENTIONS: we tested 7 rowers using the rowing machine, 12 marathon runners using the treadmill, 7 weightlifters using their own exercise equipment, and 7 healthy subjects (controls) using the cycle ergometer. MEASURES: during the tests we monitored heart rates, maximal oxygen intake, anaerobic threshold, respiratory quotient, maximum ventilation, and lactic acid. The following coagulation tests were performed before and after near-maximum exercise: prothrombin time (PT), partial activated thromboplastin time (PTT), fibrinogen (FBG), antithrombin III (ATIII), protein C (PC), protein S (PS), prothrombin fragment 1 + 2 (F1 + 2), tissue activator of plasminogen (t-PA) and its inhibitor (PAI). RESULTS: The most significant results showed a low basal PC in the rowers which decreased further after near-maximum exercise; significantly higher basal activities of ATIII, PC and PS in the marathon runners compared to the rowers; a high proportion of weightlifters showed a reduction in t-PA after exercise and an increase of PAI; the controls were the only group in which fibrinolytic activity and all the circulating anticoagulants increased after near-maximum exercise. Thus subjects who practise aerobic sports differ principally in terms of variations in inhibitors (low PC in rowers and marathon runners, increased presence of inhibitors in controls). The weightlifters did not show any significant variations, and so the kind of exercise involved (training to increase resistance and maximum strength) and the recovery times between the exercises do not seem to trigger changes in coagulation/fibrinolysis. CONCLUSIONS: We can therefore confirm that only relatively prolonged effort can trigger a mechanism beneficial to the cardiovascular system. In conclusion, physical activity benefits the coagulation system particularly as regards fibrinolysis, but certain subjects may be at risk of thrombosis and these must be identified and followed. We suggest that fibrinolytic activity be studied in athletes who practise weightlifting and have a history of cardiovascular disease, and that inhibitors (protein C in particular) be studied in rowers with a family history of thromboembolism.
Asunto(s)
Coagulación Sanguínea , Ejercicio Físico/fisiología , Deportes/fisiología , Adolescente , Adulto , Pruebas de Coagulación Sanguínea , Prueba de Esfuerzo , Fibrinólisis , Humanos , MasculinoRESUMEN
OBJECTIVE: To evaluate serum levels of prolyl-hydroxylase and helical domain of Type IV collagen, markers of hepatic fibrogenesis, in patients with HCV-positive chronic liver disease and the effects of interferon therapy on these markers. DESIGN: Prolyl-hydroxylase and Type IV collagen were determined before therapy and each month during the treatment and follow-up. METHODS: Fifty-seven HCV-positive patients were studied. All the subjects received alpha2a recombinant interferon, 6 MU subcutaneously three times a week for 4 weeks, followed by 3 MU thrice weekly for 5 months. After cessation of treatment, each patient was followed for 12 months. Prolyl-hydroxylase and helical domain of Type IV collagen were measured by using immunoenzymatic methods. HCV-RNA and HCV genotype were determined according to the method of Okamoto. RESULTS: In the patients prolyl-hydroxylase (39.8+/-8.9 ng/ml) was not different from controls (39.1+/-5.9 ng/ml). On the contrary, the patients showed a mean Type IV collagen (133.6+/-93.3 ng/ml) significantly (P < 0.01) higher than controls (100.2+/-10.5 ng/ml). A good relationship between the degree of liver fibrosis and the Type IV collagen serum level was found (r = 0.68; P < 0.005). In both responders and non-responders the Type IV collagen levels decreased during interferon therapy. During the follow-up, in responders the Type IV collagen did not show modifications, while in non-responders/relapsers it returned rapidly to the pretreatment levels (139.1+/-100.7 ng/ml). CONCLUSION: In HCV-positive chronic liver disease, prolylhydroxylase is not a good marker of hepatic fibrosis, while Type IV collagen is a useful tool for evaluating fibrogenic activity. Interferon seems to be able to reduce the liver fibrosis even without the inhibition of viral replication and independently from liver necrosis.
Asunto(s)
Colágeno/sangre , Hepatitis C/sangre , Interferón-alfa/uso terapéutico , Cirrosis Hepática/sangre , Procolágeno-Prolina Dioxigenasa/sangre , Adolescente , Adulto , Anciano , Biomarcadores/sangre , Femenino , Genotipo , Hepacivirus/aislamiento & purificación , Hepatitis C/tratamiento farmacológico , Hepatitis Crónica/sangre , Hepatitis Crónica/tratamiento farmacológico , Humanos , Interferón alfa-2 , Cirrosis Hepática/tratamiento farmacológico , Masculino , Persona de Mediana Edad , ARN Viral/análisis , Proteínas RecombinantesRESUMEN
Theophylline is widely used in preterm newborns for the prevention of idiopathic apnoeas, but few controlled studies have evaluated its effects on the nutritional and hormonal status of the infant. For this reason we have studied the effect of long term theophylline administration on 16 laboratory parameters concerning the metabolism of proteins, glucose, lipids, hormones and the glomerular function (blood: hemoglobin, glucose, albumin, prealbumin, urea nitrogen, creatinine, cholesterol, triglycerides, apolipoproteins A-I and B-100, IGF-I, IGFBP-3; urine: urea nitrogen, creatinine, C-peptide, GH). A case-control study was performed on 18 healthy preterm infants who were receiving oral theophylline for the prevention of idiopathic apnoeas. The mean duration of therapy at the moment of the balance study was 31 days (SD 12, range 12-51), the mean daily dose was 4.2 mg/kg (SD 1.0), the plasma range of theophylline concentration was 5 to 15 mg/l. As controls, 18 healthy preterm infants of comparable post-conceptional age, body weight and calories/protein intake at the moment of the study, were selected if they had been never treated with theophylline. No statistically significant differences were found between the two groups for the growth velocity or any of the parameters studied. The only notable exception was hemoglobin, which was significantly lower in theophylline treated infants (mean values 10.5 vs 12.7 g/dl, p 0.005 at t test). In synthesis, long term theophylline treatment in preterm infants seems to be safe from the point of view of growth, glucose, protein and lipid metabolism, hormones and glomerular function, but further studies are needed on the effects of theophylline on neonatal erythropoiesis.
Asunto(s)
Apnea/prevención & control , Broncodilatadores/administración & dosificación , Broncodilatadores/farmacología , Enfermedades del Prematuro/prevención & control , Teofilina/administración & dosificación , Teofilina/farmacología , Factores de Edad , Apnea/sangre , Apnea/metabolismo , Glucemia/análisis , Proteínas Sanguíneas/metabolismo , Broncodilatadores/sangre , Péptido C/sangre , Tasa de Filtración Glomerular , Crecimiento/efectos de los fármacos , Hormona del Crecimiento/orina , Humanos , Lactante , Recién Nacido , Enfermedades del Prematuro/sangre , Enfermedades del Prematuro/metabolismo , Lípidos/sangre , Teofilina/sangre , Factores de TiempoRESUMEN
The serum concentrations of 5 "nutritional" and 5 "acute phase" proteins were prospectively studied in 3 groups of newborns with nephelometric methods. Group A: 22 healthy breast fed term newborns aged 4 days; group B: 28 healthy enterally fed preterm newborns (mean gestational age 33.3 weeks); group C: 49 preterm newborns (mean gestational age 29.5 weeks) on parenteral nutrition (PN). Infants with surgical procedures, sepsis and liver or renal diseases were excluded. The serum concentrations of almost all proteins were similar or only slightly different among the 3 groups and never related to the weight and chronological or post-conceptional age. Only prealbumin, apolipoprotein A and B and C4 levels were significantly different between term and preterm newborns. Enterally fed preterm infants had lower concentrations of alpha 1 acid glycoprotein and higher albumin, transferrin and apolipoprotein A than PN fed infants. Since the observed differences were usually quite small, we suggest that--at least in clinical practice--common serum reference values of these proteins should be adopted for all healthy growing newborns, whether preterm or at term, enterally or parenterally fed. The inter-relationships between different proteins were studied. Four of the five nutritional proteins were highly correlated one with another and the same was observed for the 5 acute phase proteins. Nutritional proteins as a group did not correlate with acute phase proteins, with the only exception of alpha 1 acid glycoprotein and apolipoprotein A. Thus, the 2 groups of proteins seem to be regulated by different metabolic systems.
Asunto(s)
Proteínas de Fase Aguda , Proteínas Sanguíneas/análisis , Proteínas en la Dieta , Recien Nacido Prematuro , Apolipoproteínas/sangre , Lactancia Materna , Edad Gestacional , Humanos , Recién Nacido , Estado Nutricional , Nutrición Parenteral , Prealbúmina/análisis , Estudios Prospectivos , Estándares de ReferenciaRESUMEN
Immunoglobulins IgA, IgG and IgM and complement factors C3 and C4 have been measured in a population of premature infants to evaluate their degree of immunological maturity. All the infants were receiving complete parenteral nutrition. In parallel, the same parameters were measured in twenty two full term, healthy neonates. To explore maturation and liver function, the authors used other proteins as nutritional markers. Differences in the immunoglobulins, but not in the complement fractions were seen between the two groups. Two applications are suggested: incidence of infections and post partum maturation.
Asunto(s)
Proteínas del Sistema Complemento/análisis , Inmunoglobulinas/sangre , Recien Nacido Prematuro/inmunología , Nutrición Parenteral Total , Proteínas de Fase Aguda/análisis , Biomarcadores , Humanos , Recién Nacido , Recien Nacido Prematuro/sangre , Hígado/metabolismoAsunto(s)
Eritrocitos/metabolismo , Eritropoyetina/uso terapéutico , Estado Nutricional , Diálisis Renal , 2,3-Difosfoglicerato , Adenosina Trifosfato/sangre , Adulto , Anciano , Ácidos Difosfoglicéricos/sangre , Ingestión de Energía , Metabolismo Energético , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/uso terapéuticoAsunto(s)
Fallo Renal Crónico/dietoterapia , Cooperación del Paciente , Adulto , Anciano , Anciano de 80 o más Años , Proteínas Sanguíneas/metabolismo , Carbohidratos de la Dieta/administración & dosificación , Grasas de la Dieta/administración & dosificación , Proteínas en la Dieta/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fosfatos/orina , Fósforo Dietético/administración & dosificación , Urea/orinaAsunto(s)
Proteínas en la Dieta/administración & dosificación , Síndrome Nefrótico/dietoterapia , Estado Nutricional , Tejido Adiposo/patología , Álcalis , Antropometría , Catepsina D/metabolismo , Creatina/sangre , Humanos , Masculino , Proteínas Musculares/metabolismo , Síndrome Nefrótico/patología , Síndrome Nefrótico/fisiopatología , Solubilidad , Factores de TiempoRESUMEN
Protein energy undernutrition (PEU) and abnormalities of amino acid (AA) metabolism are common in maintenance hemodialysis patients (MHP). A new EAA formulation (BS695), enriched with valine and threonine, containing some histidine, and low in phenylalanine and methionine was recently developed. We randomly supplemented 11 MHP with this solution (treated group, TG) and 10 MHP with a standard AA solution containing both essential and non-essential AA (control group, CG). Both groups received 3.65 g of nitrogen, i.v. three times per week during hemodialysis for six months. During treatment, dietary intake remained stable in both groups. Before treatment, after three and six months of treatment, and six months after the end of treatment, we determined routine blood chemistries, anthropometry, serum protein levels (albumin, transferrin), delayed cutaneous sensitivity (Multi-test), protein catabolic rate (PCR), plasma AA content and motor nerve conduction velocity (MNCV). Before treatment PEU, predominantly of marasmic type, was common. After treatment anthropometry and immune response were unchanged in both groups; PCR increased more in CG than in TG; serum albumin levels decreased significantly only in CG; MNCV improved in TG and worsened in CG. These preliminary results suggest that this new EAA formulation may have beneficial effects on some nutrition related abnormalities of MHP. Better results might occur with long-term AA supplementation, particularly if it is associated with a higher energy intake.